CUPERTINO - In a significant turn of events, Apple (NASDAQ:AAPL) has disabled the blood oxygen monitoring feature on its Series 9 and Ultra 2 smartwatches. This move comes as a response to an enforcement action by the U.S. Court of Appeals, which upheld an International Trade Commission ruling from October. The court's decision is part of a broader patent dispute with medical technology company Masimo (NASDAQ:MASI), leading to an import ban on the affected Apple products.
The blood oxygen monitoring feature is a key health-related function on the latest Apple smartwatches, and its removal marks a notable change for users who rely on the feature for health tracking. Apple's compliance indicates the company's adherence to the legal rulings and the complexities of navigating international patent laws.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.